A member enters a Marylebone converted retail space, takes off their clothes, and waits inside a pod for an hour while cameras and lasers map every mole on their body. An hour later, a clinician walks them through data on body composition, metabolic risk, and blood markers that would often need months and multiple referrals to compile in most NHS paths. They pay £299, book next year's appointment on the way out, and leave with a level of personal health intelligence that no GP surgery in the country can currently match in a single sitting. This is not a thought experiment. Daniel Ek and Hjalmar Nilsonne of Spotify founded Neko Health, which recently announced a $700 million Series C financing round prior to its first US clinics. The company is supported by a list of investors that resembles a Davos guest list and has already been validated by over 100,000 members from Sweden and the UK.

The instinct in NHS circles will be to file this under private wellness indulgence, another subscription health product for people who can already afford to worry less. That instinct would be a mistake. Neko's timing is not incidental. NHS England's own planning framework has spent the past year committing, on paper at least, to a shift from sickness management to proactive population health, one of the three foundational changes in the government's ten year plan. The ambition is the same one Neko is monetising: catch disease before it becomes expensive, keep people out of hospital, use data rather than waiting lists to manage risk. The difference is that Neko has already built it, priced it, and scaled it across four London locations plus Manchester and Birmingham, while the NHS version remains largely a planning document and a set of pilot schemes contending with workforce shortages and community care capacity that has not kept pace with rhetoric.

Neko's own data shows three in four returning members with previously identified severe or life-threatening conditions now have those conditions under control, a genuinely striking outcome. But those members were self-selecting and paying, which means the model works precisely for the population least likely to be falling through NHS gaps in the first place. When a Neko scan flags an abnormal biomarker or a suspicious mole, that finding does not vanish into a private treatment pathway. It gets referred into NHS diagnostics, oncology, dermatology, wherever the state system picks up where the private scan leaves off. Every incidental finding from a fast-growing membership base becomes, eventually, NHS workload, arriving with no corresponding transfer of funding or capacity. A prevention company that scales faster than public prevention infrastructure does not relieve pressure on the system. It redirects it, and concentrates the redirection among people already inclined and able to seek care early, widening rather than narrowing the gap the ten year plan claims to be closing.

For NHS leaders and integrated care boards already stretched managing Advanced Foundation Trust status, digital transformation contracts and workforce plans that remain years from delivery, Neko's rise is a signal worth reading carefully rather than dismissing. It demonstrates that the public appetite and willingness to pay for structured, data-rich preventive care exists and is growing, which strengthens the political case for investment in NHS prevention infrastructure. It also shows that the state runs the risk of taking on the downstream costs of a system it did not create and cannot yet match in terms of speed or user experience if it does not have a cogent public plan for absorbing referrals made by the privately owned prevention sector and if that strategy does not incorporate parity of access.

Life sciences and health-tech investors watching this raise will draw a simple lesson: British and Swedish consumers will pay for prevention when it is delivered with genuine polish and speed, and international capital is willing to back that at scale. A less comfortable one should be drawn by policymakers. The NHS is not competing with Neko for patients. It is competing with Neko for the political and financial permission to build the same thing at public scale, and right now the private sector has a three year head start.